Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Research Report 2026

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 Adherent Culture
1.2.3 Suspension Culture
1.3 Market by Application
1.3.1 Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Growth by Application: 2021 vs 2025 vs 2032
1.3.2 Vaccine Development
1.3.3 Gene Therapy
1.3.4 Academic Scientific Research Institution
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Perspective (2021–2032)
2.2 Global Adeno-Associated Virus (AAV) Vector Production CDMO Growth Trends by Region
2.2.1 Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Adeno-Associated Virus (AAV) Vector Production CDMO Historic Market Size by Region (2021–2026)
2.2.3 Adeno-Associated Virus (AAV) Vector Production CDMO Forecasted Market Size by Region (2027–2032)
2.3 Adeno-Associated Virus (AAV) Vector Production CDMO Market Dynamics
2.3.1 Adeno-Associated Virus (AAV) Vector Production CDMO Industry Trends
2.3.2 Adeno-Associated Virus (AAV) Vector Production CDMO Market Drivers
2.3.3 Adeno-Associated Virus (AAV) Vector Production CDMO Market Challenges
2.3.4 Adeno-Associated Virus (AAV) Vector Production CDMO Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Adeno-Associated Virus (AAV) Vector Production CDMO Players by Revenue
3.1.1 Global Top Adeno-Associated Virus (AAV) Vector Production CDMO Players by Revenue (2021–2026)
3.1.2 Global Adeno-Associated Virus (AAV) Vector Production CDMO Revenue Market Share by Players (2021–2026)
3.2 Global Top Adeno-Associated Virus (AAV) Vector Production CDMO Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Adeno-Associated Virus (AAV) Vector Production CDMO Revenue
3.4 Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Concentration Ratio
3.4.1 Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Adeno-Associated Virus (AAV) Vector Production CDMO Revenue in 2025
3.5 Global Key Players of Adeno-Associated Virus (AAV) Vector Production CDMO Head Offices and Areas Served
3.6 Global Key Players of Adeno-Associated Virus (AAV) Vector Production CDMO, Products and Applications
3.7 Global Key Players of Adeno-Associated Virus (AAV) Vector Production CDMO, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 Adeno-Associated Virus (AAV) Vector Production CDMO Breakdown Data by Type
4.1 Global Adeno-Associated Virus (AAV) Vector Production CDMO Historic Market Size by Type (2021–2026)
4.2 Global Adeno-Associated Virus (AAV) Vector Production CDMO Forecasted Market Size by Type (2027–2032)
5 Adeno-Associated Virus (AAV) Vector Production CDMO Breakdown Data by Application
5.1 Global Adeno-Associated Virus (AAV) Vector Production CDMO Historic Market Size by Application (2021–2026)
5.2 Global Adeno-Associated Virus (AAV) Vector Production CDMO Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America Adeno-Associated Virus (AAV) Vector Production CDMO Market Size (2021–2032)
6.2 North America Adeno-Associated Virus (AAV) Vector Production CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Country (2021–2026)
6.4 North America Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Adeno-Associated Virus (AAV) Vector Production CDMO Market Size (2021–2032)
7.2 Europe Adeno-Associated Virus (AAV) Vector Production CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Country (2021–2026)
7.4 Europe Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Adeno-Associated Virus (AAV) Vector Production CDMO Market Size (2021–2032)
8.2 Asia-Pacific Adeno-Associated Virus (AAV) Vector Production CDMO Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Region (2021–2026)
8.4 Asia-Pacific Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Adeno-Associated Virus (AAV) Vector Production CDMO Market Size (2021–2032)
9.2 Latin America Adeno-Associated Virus (AAV) Vector Production CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Country (2021–2026)
9.4 Latin America Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Adeno-Associated Virus (AAV) Vector Production CDMO Market Size (2021–2032)
10.2 Middle East & Africa Adeno-Associated Virus (AAV) Vector Production CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Country (2021–2026)
10.4 Middle East & Africa Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Thermo Fisher Scientific
11.1.1 Thermo Fisher Scientific Company Details
11.1.2 Thermo Fisher Scientific Business Overview
11.1.3 Thermo Fisher Scientific Adeno-Associated Virus (AAV) Vector Production CDMO Introduction
11.1.4 Thermo Fisher Scientific Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
11.1.5 Thermo Fisher Scientific Recent Development
11.2 Lonza
11.2.1 Lonza Company Details
11.2.2 Lonza Business Overview
11.2.3 Lonza Adeno-Associated Virus (AAV) Vector Production CDMO Introduction
11.2.4 Lonza Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
11.2.5 Lonza Recent Development
11.3 Catalent
11.3.1 Catalent Company Details
11.3.2 Catalent Business Overview
11.3.3 Catalent Adeno-Associated Virus (AAV) Vector Production CDMO Introduction
11.3.4 Catalent Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
11.3.5 Catalent Recent Development
11.4 Charles River
11.4.1 Charles River Company Details
11.4.2 Charles River Business Overview
11.4.3 Charles River Adeno-Associated Virus (AAV) Vector Production CDMO Introduction
11.4.4 Charles River Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
11.4.5 Charles River Recent Development
11.5 Merck
11.5.1 Merck Company Details
11.5.2 Merck Business Overview
11.5.3 Merck Adeno-Associated Virus (AAV) Vector Production CDMO Introduction
11.5.4 Merck Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
11.5.5 Merck Recent Development
11.6 SK pharmteco
11.6.1 SK pharmteco Company Details
11.6.2 SK pharmteco Business Overview
11.6.3 SK pharmteco Adeno-Associated Virus (AAV) Vector Production CDMO Introduction
11.6.4 SK pharmteco Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
11.6.5 SK pharmteco Recent Development
11.7 Oxford Biomedica
11.7.1 Oxford Biomedica Company Details
11.7.2 Oxford Biomedica Business Overview
11.7.3 Oxford Biomedica Adeno-Associated Virus (AAV) Vector Production CDMO Introduction
11.7.4 Oxford Biomedica Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
11.7.5 Oxford Biomedica Recent Development
11.8 AGC Biologics（MolMed）
11.8.1 AGC Biologics（MolMed） Company Details
11.8.2 AGC Biologics（MolMed） Business Overview
11.8.3 AGC Biologics（MolMed） Adeno-Associated Virus (AAV) Vector Production CDMO Introduction
11.8.4 AGC Biologics（MolMed） Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
11.8.5 AGC Biologics（MolMed） Recent Development
11.9 Gene Universal
11.9.1 Gene Universal Company Details
11.9.2 Gene Universal Business Overview
11.9.3 Gene Universal Adeno-Associated Virus (AAV) Vector Production CDMO Introduction
11.9.4 Gene Universal Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
11.9.5 Gene Universal Recent Development
11.10 Polyplus (Sartorius)
11.10.1 Polyplus (Sartorius) Company Details
11.10.2 Polyplus (Sartorius) Business Overview
11.10.3 Polyplus (Sartorius) Adeno-Associated Virus (AAV) Vector Production CDMO Introduction
11.10.4 Polyplus (Sartorius) Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
11.10.5 Polyplus (Sartorius) Recent Development
11.11 CCRM
11.11.1 CCRM Company Details
11.11.2 CCRM Business Overview
11.11.3 CCRM Adeno-Associated Virus (AAV) Vector Production CDMO Introduction
11.11.4 CCRM Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
11.11.5 CCRM Recent Development
11.12 FUJIFILM Diosynth Biotechnologies
11.12.1 FUJIFILM Diosynth Biotechnologies Company Details
11.12.2 FUJIFILM Diosynth Biotechnologies Business Overview
11.12.3 FUJIFILM Diosynth Biotechnologies Adeno-Associated Virus (AAV) Vector Production CDMO Introduction
11.12.4 FUJIFILM Diosynth Biotechnologies Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
11.12.5 FUJIFILM Diosynth Biotechnologies Recent Development
11.13 Biovian
11.13.1 Biovian Company Details
11.13.2 Biovian Business Overview
11.13.3 Biovian Adeno-Associated Virus (AAV) Vector Production CDMO Introduction
11.13.4 Biovian Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
11.13.5 Biovian Recent Development
11.14 Miltenyi Bioindustry
11.14.1 Miltenyi Bioindustry Company Details
11.14.2 Miltenyi Bioindustry Business Overview
11.14.3 Miltenyi Bioindustry Adeno-Associated Virus (AAV) Vector Production CDMO Introduction
11.14.4 Miltenyi Bioindustry Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
11.14.5 Miltenyi Bioindustry Recent Development
11.15 Aldevron
11.15.1 Aldevron Company Details
11.15.2 Aldevron Business Overview
11.15.3 Aldevron Adeno-Associated Virus (AAV) Vector Production CDMO Introduction
11.15.4 Aldevron Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
11.15.5 Aldevron Recent Development
11.16 Takara Bio
11.16.1 Takara Bio Company Details
11.16.2 Takara Bio Business Overview
11.16.3 Takara Bio Adeno-Associated Virus (AAV) Vector Production CDMO Introduction
11.16.4 Takara Bio Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
11.16.5 Takara Bio Recent Development
11.17 Yposkesi
11.17.1 Yposkesi Company Details
11.17.2 Yposkesi Business Overview
11.17.3 Yposkesi Adeno-Associated Virus (AAV) Vector Production CDMO Introduction
11.17.4 Yposkesi Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
11.17.5 Yposkesi Recent Development
11.18 Genezen
11.18.1 Genezen Company Details
11.18.2 Genezen Business Overview
11.18.3 Genezen Adeno-Associated Virus (AAV) Vector Production CDMO Introduction
11.18.4 Genezen Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
11.18.5 Genezen Recent Development
11.19 Exthera
11.19.1 Exthera Company Details
11.19.2 Exthera Business Overview
11.19.3 Exthera Adeno-Associated Virus (AAV) Vector Production CDMO Introduction
11.19.4 Exthera Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
11.19.5 Exthera Recent Development
11.20 GenScript ProBio
11.20.1 GenScript ProBio Company Details
11.20.2 GenScript ProBio Business Overview
11.20.3 GenScript ProBio Adeno-Associated Virus (AAV) Vector Production CDMO Introduction
11.20.4 GenScript ProBio Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
11.20.5 GenScript ProBio Recent Development
11.21 EurekaBio
11.21.1 EurekaBio Company Details
11.21.2 EurekaBio Business Overview
11.21.3 EurekaBio Adeno-Associated Virus (AAV) Vector Production CDMO Introduction
11.21.4 EurekaBio Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
11.21.5 EurekaBio Recent Development
11.22 Obio Technology
11.22.1 Obio Technology Company Details
11.22.2 Obio Technology Business Overview
11.22.3 Obio Technology Adeno-Associated Virus (AAV) Vector Production CDMO Introduction
11.22.4 Obio Technology Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
11.22.5 Obio Technology Recent Development
11.23 GeneSail Biotech
11.23.1 GeneSail Biotech Company Details
11.23.2 GeneSail Biotech Business Overview
11.23.3 GeneSail Biotech Adeno-Associated Virus (AAV) Vector Production CDMO Introduction
11.23.4 GeneSail Biotech Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
11.23.5 GeneSail Biotech Recent Development
11.24 VectorBuilder
11.24.1 VectorBuilder Company Details
11.24.2 VectorBuilder Business Overview
11.24.3 VectorBuilder Adeno-Associated Virus (AAV) Vector Production CDMO Introduction
11.24.4 VectorBuilder Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
11.24.5 VectorBuilder Recent Development
11.25 WuXi ATU
11.25.1 WuXi ATU Company Details
11.25.2 WuXi ATU Business Overview
11.25.3 WuXi ATU Adeno-Associated Virus (AAV) Vector Production CDMO Introduction
11.25.4 WuXi ATU Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
11.25.5 WuXi ATU Recent Development
11.26 Ubrigene
11.26.1 Ubrigene Company Details
11.26.2 Ubrigene Business Overview
11.26.3 Ubrigene Adeno-Associated Virus (AAV) Vector Production CDMO Introduction
11.26.4 Ubrigene Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
11.26.5 Ubrigene Recent Development
11.27 Porton Biologics
11.27.1 Porton Biologics Company Details
11.27.2 Porton Biologics Business Overview
11.27.3 Porton Biologics Adeno-Associated Virus (AAV) Vector Production CDMO Introduction
11.27.4 Porton Biologics Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
11.27.5 Porton Biologics Recent Development
11.28 Pharmaron
11.28.1 Pharmaron Company Details
11.28.2 Pharmaron Business Overview
11.28.3 Pharmaron Adeno-Associated Virus (AAV) Vector Production CDMO Introduction
11.28.4 Pharmaron Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
11.28.5 Pharmaron Recent Development
11.29 PackGene Biotechnology
11.29.1 PackGene Biotechnology Company Details
11.29.2 PackGene Biotechnology Business Overview
11.29.3 PackGene Biotechnology Adeno-Associated Virus (AAV) Vector Production CDMO Introduction
11.29.4 PackGene Biotechnology Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
11.29.5 PackGene Biotechnology Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer

List of Tables
Table 1. Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
Table 2. Key Players of Adherent Culture
Table 3. Key Players of Suspension Culture
Table 4. Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
Table 5. Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 6. Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Region (US$ Million), 2021–2026
Table 7. Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Share by Region (2021–2026)
Table 8. Global Adeno-Associated Virus (AAV) Vector Production CDMO Forecasted Market Size by Region (US$ Million), 2027–2032
Table 9. Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Share by Region (2027–2032)
Table 10. Adeno-Associated Virus (AAV) Vector Production CDMO Market Trends
Table 11. Adeno-Associated Virus (AAV) Vector Production CDMO Market Drivers
Table 12. Adeno-Associated Virus (AAV) Vector Production CDMO Market Challenges
Table 13. Adeno-Associated Virus (AAV) Vector Production CDMO Market Restraints
Table 14. Global Adeno-Associated Virus (AAV) Vector Production CDMO Revenue by Players (US$ Million), 2021–2026
Table 15. Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Share by Players (2021–2026)
Table 16. Global Top Adeno-Associated Virus (AAV) Vector Production CDMO Players by Tier (Tier 1, Tier 2, and Tier 3), based on Adeno-Associated Virus (AAV) Vector Production CDMO Revenue, 2025
Table 17. Ranking of Global Top Adeno-Associated Virus (AAV) Vector Production CDMO Companies by Revenue (US$ Million) in 2025
Table 18. Global 5 Largest Players Market Share by Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (CR5 and HHI), 2021–2026
Table 19. Global Key Players of Adeno-Associated Virus (AAV) Vector Production CDMO, Headquarters and Area Served
Table 20. Global Key Players of Adeno-Associated Virus (AAV) Vector Production CDMO, Products and Applications
Table 21. Global Key Players of Adeno-Associated Virus (AAV) Vector Production CDMO, Date of General Availability (GA)
Table 22. Mergers and Acquisitions, Expansion Plans
Table 23. Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Type (US$ Million), 2021–2026
Table 24. Global Adeno-Associated Virus (AAV) Vector Production CDMO Revenue Market Share by Type (2021–2026)
Table 25. Global Adeno-Associated Virus (AAV) Vector Production CDMO Forecasted Market Size by Type (US$ Million), 2027–2032
Table 26. Global Adeno-Associated Virus (AAV) Vector Production CDMO Revenue Market Share by Type (2027–2032)
Table 27. Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Application (US$ Million), 2021–2026
Table 28. Global Adeno-Associated Virus (AAV) Vector Production CDMO Revenue Market Share by Application (2021–2026)
Table 29. Global Adeno-Associated Virus (AAV) Vector Production CDMO Forecasted Market Size by Application (US$ Million), 2027–2032
Table 30. Global Adeno-Associated Virus (AAV) Vector Production CDMO Revenue Market Share by Application (2027–2032)
Table 31. North America Adeno-Associated Virus (AAV) Vector Production CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 32. North America Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Country (US$ Million), 2021–2026
Table 33. North America Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Country (US$ Million), 2027–2032
Table 34. Europe Adeno-Associated Virus (AAV) Vector Production CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 35. Europe Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Country (US$ Million), 2021–2026
Table 36. Europe Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Country (US$ Million), 2027–2032
Table 37. Asia-Pacific Adeno-Associated Virus (AAV) Vector Production CDMO Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
Table 38. Asia-Pacific Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Region (US$ Million), 2021–2026
Table 39. Asia-Pacific Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Region (US$ Million), 2027–2032
Table 40. Latin America Adeno-Associated Virus (AAV) Vector Production CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 41. Latin America Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Country (US$ Million), 2021–2026
Table 42. Latin America Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Country (US$ Million), 2027–2032
Table 43. Middle East & Africa Adeno-Associated Virus (AAV) Vector Production CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 44. Middle East & Africa Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Country (US$ Million), 2021–2026
Table 45. Middle East & Africa Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Country (US$ Million), 2027–2032
Table 46. Thermo Fisher Scientific Company Details
Table 47. Thermo Fisher Scientific Business Overview
Table 48. Thermo Fisher Scientific Adeno-Associated Virus (AAV) Vector Production CDMO Product
Table 49. Thermo Fisher Scientific Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (US$ Million), 2021–2026
Table 50. Thermo Fisher Scientific Recent Development
Table 51. Lonza Company Details
Table 52. Lonza Business Overview
Table 53. Lonza Adeno-Associated Virus (AAV) Vector Production CDMO Product
Table 54. Lonza Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (US$ Million), 2021–2026
Table 55. Lonza Recent Development
Table 56. Catalent Company Details
Table 57. Catalent Business Overview
Table 58. Catalent Adeno-Associated Virus (AAV) Vector Production CDMO Product
Table 59. Catalent Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (US$ Million), 2021–2026
Table 60. Catalent Recent Development
Table 61. Charles River Company Details
Table 62. Charles River Business Overview
Table 63. Charles River Adeno-Associated Virus (AAV) Vector Production CDMO Product
Table 64. Charles River Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (US$ Million), 2021–2026
Table 65. Charles River Recent Development
Table 66. Merck Company Details
Table 67. Merck Business Overview
Table 68. Merck Adeno-Associated Virus (AAV) Vector Production CDMO Product
Table 69. Merck Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (US$ Million), 2021–2026
Table 70. Merck Recent Development
Table 71. SK pharmteco Company Details
Table 72. SK pharmteco Business Overview
Table 73. SK pharmteco Adeno-Associated Virus (AAV) Vector Production CDMO Product
Table 74. SK pharmteco Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (US$ Million), 2021–2026
Table 75. SK pharmteco Recent Development
Table 76. Oxford Biomedica Company Details
Table 77. Oxford Biomedica Business Overview
Table 78. Oxford Biomedica Adeno-Associated Virus (AAV) Vector Production CDMO Product
Table 79. Oxford Biomedica Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (US$ Million), 2021–2026
Table 80. Oxford Biomedica Recent Development
Table 81. AGC Biologics（MolMed） Company Details
Table 82. AGC Biologics（MolMed） Business Overview
Table 83. AGC Biologics（MolMed） Adeno-Associated Virus (AAV) Vector Production CDMO Product
Table 84. AGC Biologics（MolMed） Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (US$ Million), 2021–2026
Table 85. AGC Biologics（MolMed） Recent Development
Table 86. Gene Universal Company Details
Table 87. Gene Universal Business Overview
Table 88. Gene Universal Adeno-Associated Virus (AAV) Vector Production CDMO Product
Table 89. Gene Universal Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (US$ Million), 2021–2026
Table 90. Gene Universal Recent Development
Table 91. Polyplus (Sartorius) Company Details
Table 92. Polyplus (Sartorius) Business Overview
Table 93. Polyplus (Sartorius) Adeno-Associated Virus (AAV) Vector Production CDMO Product
Table 94. Polyplus (Sartorius) Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (US$ Million), 2021–2026
Table 95. Polyplus (Sartorius) Recent Development
Table 96. CCRM Company Details
Table 97. CCRM Business Overview
Table 98. CCRM Adeno-Associated Virus (AAV) Vector Production CDMO Product
Table 99. CCRM Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (US$ Million), 2021–2026
Table 100. CCRM Recent Development
Table 101. FUJIFILM Diosynth Biotechnologies Company Details
Table 102. FUJIFILM Diosynth Biotechnologies Business Overview
Table 103. FUJIFILM Diosynth Biotechnologies Adeno-Associated Virus (AAV) Vector Production CDMO Product
Table 104. FUJIFILM Diosynth Biotechnologies Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (US$ Million), 2021–2026
Table 105. FUJIFILM Diosynth Biotechnologies Recent Development
Table 106. Biovian Company Details
Table 107. Biovian Business Overview
Table 108. Biovian Adeno-Associated Virus (AAV) Vector Production CDMO Product
Table 109. Biovian Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (US$ Million), 2021–2026
Table 110. Biovian Recent Development
Table 111. Miltenyi Bioindustry Company Details
Table 112. Miltenyi Bioindustry Business Overview
Table 113. Miltenyi Bioindustry Adeno-Associated Virus (AAV) Vector Production CDMO Product
Table 114. Miltenyi Bioindustry Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (US$ Million), 2021–2026
Table 115. Miltenyi Bioindustry Recent Development
Table 116. Aldevron Company Details
Table 117. Aldevron Business Overview
Table 118. Aldevron Adeno-Associated Virus (AAV) Vector Production CDMO Product
Table 119. Aldevron Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (US$ Million), 2021–2026
Table 120. Aldevron Recent Development
Table 121. Takara Bio Company Details
Table 122. Takara Bio Business Overview
Table 123. Takara Bio Adeno-Associated Virus (AAV) Vector Production CDMO Product
Table 124. Takara Bio Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (US$ Million), 2021–2026
Table 125. Takara Bio Recent Development
Table 126. Yposkesi Company Details
Table 127. Yposkesi Business Overview
Table 128. Yposkesi Adeno-Associated Virus (AAV) Vector Production CDMO Product
Table 129. Yposkesi Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (US$ Million), 2021–2026
Table 130. Yposkesi Recent Development
Table 131. Genezen Company Details
Table 132. Genezen Business Overview
Table 133. Genezen Adeno-Associated Virus (AAV) Vector Production CDMO Product
Table 134. Genezen Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (US$ Million), 2021–2026
Table 135. Genezen Recent Development
Table 136. Exthera Company Details
Table 137. Exthera Business Overview
Table 138. Exthera Adeno-Associated Virus (AAV) Vector Production CDMO Product
Table 139. Exthera Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (US$ Million), 2021–2026
Table 140. Exthera Recent Development
Table 141. GenScript ProBio Company Details
Table 142. GenScript ProBio Business Overview
Table 143. GenScript ProBio Adeno-Associated Virus (AAV) Vector Production CDMO Product
Table 144. GenScript ProBio Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (US$ Million), 2021–2026
Table 145. GenScript ProBio Recent Development
Table 146. EurekaBio Company Details
Table 147. EurekaBio Business Overview
Table 148. EurekaBio Adeno-Associated Virus (AAV) Vector Production CDMO Product
Table 149. EurekaBio Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (US$ Million), 2021–2026
Table 150. EurekaBio Recent Development
Table 151. Obio Technology Company Details
Table 152. Obio Technology Business Overview
Table 153. Obio Technology Adeno-Associated Virus (AAV) Vector Production CDMO Product
Table 154. Obio Technology Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (US$ Million), 2021–2026
Table 155. Obio Technology Recent Development
Table 156. GeneSail Biotech Company Details
Table 157. GeneSail Biotech Business Overview
Table 158. GeneSail Biotech Adeno-Associated Virus (AAV) Vector Production CDMO Product
Table 159. GeneSail Biotech Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (US$ Million), 2021–2026
Table 160. GeneSail Biotech Recent Development
Table 161. VectorBuilder Company Details
Table 162. VectorBuilder Business Overview
Table 163. VectorBuilder Adeno-Associated Virus (AAV) Vector Production CDMO Product
Table 164. VectorBuilder Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (US$ Million), 2021–2026
Table 165. VectorBuilder Recent Development
Table 166. WuXi ATU Company Details
Table 167. WuXi ATU Business Overview
Table 168. WuXi ATU Adeno-Associated Virus (AAV) Vector Production CDMO Product
Table 169. WuXi ATU Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (US$ Million), 2021–2026
Table 170. WuXi ATU Recent Development
Table 171. Ubrigene Company Details
Table 172. Ubrigene Business Overview
Table 173. Ubrigene Adeno-Associated Virus (AAV) Vector Production CDMO Product
Table 174. Ubrigene Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (US$ Million), 2021–2026
Table 175. Ubrigene Recent Development
Table 176. Porton Biologics Company Details
Table 177. Porton Biologics Business Overview
Table 178. Porton Biologics Adeno-Associated Virus (AAV) Vector Production CDMO Product
Table 179. Porton Biologics Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (US$ Million), 2021–2026
Table 180. Porton Biologics Recent Development
Table 181. Pharmaron Company Details
Table 182. Pharmaron Business Overview
Table 183. Pharmaron Adeno-Associated Virus (AAV) Vector Production CDMO Product
Table 184. Pharmaron Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (US$ Million), 2021–2026
Table 185. Pharmaron Recent Development
Table 186. PackGene Biotechnology Company Details
Table 187. PackGene Biotechnology Business Overview
Table 188. PackGene Biotechnology Adeno-Associated Virus (AAV) Vector Production CDMO Product
Table 189. PackGene Biotechnology Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (US$ Million), 2021–2026
Table 190. PackGene Biotechnology Recent Development
Table 191. Research Programs/Design for This Report
Table 192. Key Data Information from Secondary Sources
Table 193. Key Data Information from Primary Sources
Table 194. Authors List of This Report


List of Figures
Figure 1. Adeno-Associated Virus (AAV) Vector Production CDMO Picture
Figure 2. Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Size Comparison by Type (US$ Million), 2021–2032
Figure 3. Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Share by Type: 2025 vs 2032
Figure 4. Adherent Culture Features
Figure 5. Suspension Culture Features
Figure 6. Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Application (US$ Million), 2021–2032
Figure 7. Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Share by Application: 2025 vs 2032
Figure 8. Vaccine Development Case Studies
Figure 9. Gene Therapy Case Studies
Figure 10. Academic Scientific Research Institution Case Studies
Figure 11. Others Case Studies
Figure 12. Adeno-Associated Virus (AAV) Vector Production CDMO Report Years Considered
Figure 13. Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Size (US$ Million), Year-over-Year: 2021–2032
Figure 14. Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 15. Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Share by Region: 2025 vs 2032
Figure 16. Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Share by Players in 2025
Figure 17. Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 18. The Top 10 and 5 Players Market Share by Adeno-Associated Virus (AAV) Vector Production CDMO Revenue in 2025
Figure 19. North America Adeno-Associated Virus (AAV) Vector Production CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 20. North America Adeno-Associated Virus (AAV) Vector Production CDMO Market Share by Country (2021–2032)
Figure 21. United States Adeno-Associated Virus (AAV) Vector Production CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 22. Canada Adeno-Associated Virus (AAV) Vector Production CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 23. Europe Adeno-Associated Virus (AAV) Vector Production CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 24. Europe Adeno-Associated Virus (AAV) Vector Production CDMO Market Share by Country (2021–2032)
Figure 25. Germany Adeno-Associated Virus (AAV) Vector Production CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 26. France Adeno-Associated Virus (AAV) Vector Production CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 27. U.K. Adeno-Associated Virus (AAV) Vector Production CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 28. Italy Adeno-Associated Virus (AAV) Vector Production CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 29. Russia Adeno-Associated Virus (AAV) Vector Production CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 30. Ireland Adeno-Associated Virus (AAV) Vector Production CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 31. Asia-Pacific Adeno-Associated Virus (AAV) Vector Production CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 32. Asia-Pacific Adeno-Associated Virus (AAV) Vector Production CDMO Market Share by Region (2021–2032)
Figure 33. China Adeno-Associated Virus (AAV) Vector Production CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 34. Japan Adeno-Associated Virus (AAV) Vector Production CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 35. South Korea Adeno-Associated Virus (AAV) Vector Production CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 36. Southeast Asia Adeno-Associated Virus (AAV) Vector Production CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 37. India Adeno-Associated Virus (AAV) Vector Production CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 38. Australia & New Zealand Adeno-Associated Virus (AAV) Vector Production CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 39. Latin America Adeno-Associated Virus (AAV) Vector Production CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 40. Latin America Adeno-Associated Virus (AAV) Vector Production CDMO Market Share by Country (2021–2032)
Figure 41. Mexico Adeno-Associated Virus (AAV) Vector Production CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 42. Brazil Adeno-Associated Virus (AAV) Vector Production CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 43. Middle East & Africa Adeno-Associated Virus (AAV) Vector Production CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 44. Middle East & Africa Adeno-Associated Virus (AAV) Vector Production CDMO Market Share by Country (2021–2032)
Figure 45. Israel Adeno-Associated Virus (AAV) Vector Production CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 46. Saudi Arabia Adeno-Associated Virus (AAV) Vector Production CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 47. UAE Adeno-Associated Virus (AAV) Vector Production CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 48. Thermo Fisher Scientific Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
Figure 49. Lonza Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
Figure 50. Catalent Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
Figure 51. Charles River Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
Figure 52. Merck Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
Figure 53. SK pharmteco Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
Figure 54. Oxford Biomedica Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
Figure 55. AGC Biologics（MolMed） Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
Figure 56. Gene Universal Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
Figure 57. Polyplus (Sartorius) Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
Figure 58. CCRM Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
Figure 59. FUJIFILM Diosynth Biotechnologies Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
Figure 60. Biovian Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
Figure 61. Miltenyi Bioindustry Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
Figure 62. Aldevron Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
Figure 63. Takara Bio Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
Figure 64. Yposkesi Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
Figure 65. Genezen Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
Figure 66. Exthera Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
Figure 67. GenScript ProBio Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
Figure 68. EurekaBio Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
Figure 69. Obio Technology Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
Figure 70. GeneSail Biotech Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
Figure 71. VectorBuilder Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
Figure 72. WuXi ATU Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
Figure 73. Ubrigene Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
Figure 74. Porton Biologics Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
Figure 75. Pharmaron Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
Figure 76. PackGene Biotechnology Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
Figure 77. Bottom-up and Top-down Approaches for This Report
Figure 78. Data Triangulation
Figure 79. Key Executives Interviewed

Your Name

Your E-mail

Your message

Submit